Source: International Congress 2014 – Animal models in respiratory drug development
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
G. Villetti, P. T. Bolzoni, F. Bassani, M. Bergamaschi, P. L. Caruso, L. Battipaglia, A. Sala, F. Facchinetti, C. Carnini, M. Civelli (Parma, Milan, Italy). In vivo efficacy of CHF6001, an inhaled PDE4 inhibitor with a wide therapeutic window. Eur Respir J 2014; 44: Suppl. 58, 1787

Member's Comments

No comment yet.

Related content which might interest you: In vitro profile of the new inhaled pan-JAK inhibitor LAS194046 Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 In vitro characterization of a novel inhaled PI3Kd inhibitor LAS194223 Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 A combination of thyme and ivy exerts potent anti-inflammatory and mucus-normalizing activity in vivo and inhibits 5-LO and PDE4 Source: International Congress 2014 – Animal models in respiratory drug development Year: 2014 CHI-91040, a novel inhaled p38α inhibitor, counteracts lung inflammation induced by IL-1β in the rat Source: International Congress 2016 – ILD: from the bench to the bedside Year: 2016 Effect of the combination of doxofylline and montelukast on LPS-induced leukocyte migration to the lung Source: International Congress 2014 – Animal models in respiratory drug development Year: 2014 Preclinical characterization of CPL-302-201, a novel, highly potent and selective PI3Kδ inhibitor for the treatment of inflammatory disorders Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 RP6503, a novel and selective PI3K δ/gamma inhibitor, potentiates the effect of steroids in pre-clinical models of COPD Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 Pharmacological profile and efficacy of GLPG1690, a novel ATX inhibitor for COPD treatment Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD Year: 2015 In vitro pharmacological characterization of CHF6001, a novel selective phosphodiesterase 4 (PDE4) inhibitor with a robust anti-inflammatory profile Source: International Congress 2014 – Novel targets and drugs for asthma and COPD Year: 2014 Therapeutic potential of CPL-407-105 – Novel potent JAK/STAT pathway inhibitor for the treatment of asthma Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 Additive anti-inflammatory effect of glucocorticoids and PDE4 inhibitors on COPD CD8 cells Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 Prediction of human lung PK for AZD7624, an inhaled P38 inhibitor for the treatment of COPD Source: International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis Year: 2015 The anti-inflammatory effects of PF03715455 and roflumilast on both cellular and tissue inflammation in a mouse model of COPD Source: Annual Congress 2013 –New drugs in respiratory medicine Year: 2013 Bronchoprotective activity and safety assessment of two novel dual-acting MABA compounds (LAS190792 and LAS191351) in dogs Source: International Congress 2014 – Novel targets and drugs for asthma and COPD Year: 2014 The novel elastase inhibitor BAY 85-8501 provides a new approach in the treatment of pulmonary diseases Source: International Congress 2014 – New drugs for asthma, COPD and pulmonary fibrosis Year: 2014 Anti-inflammatory effects of the novel PDE4 inhibitor CHF6001 on virus inducible cytokines Source: International Congress 2014 – Allergy and asthma: novel findings based on human cell biology Year: 2014 In vitro pharmacological characterization of two novel dual-acting MABA compounds (LAS190792 and LAS191351) Source: International Congress 2014 – Novel targets and drugs for asthma and COPD Year: 2014 A novel inhaled PI3Kδ inhibitor, LAS194223 reduces allergen-induced airway inflammation in rat Source: International Congress 2014 – New drugs for asthma, COPD and pulmonary fibrosis Year: 2014 The effect of the inhaled PDE4 inhibitor CHF6001 on allergen-induced inflammation in asthmatics Source: International Congress 2014 – Asthma and COPD management Year: 2014 AZD5069: Pharmacological profile of a CXCR2 antagonist in development for the treatment of respiratory disorders Source: International Congress 2014 – Novel evidence relating to respiratory treatment development Year: 2014